<DOC>
	<DOCNO>NCT00937794</DOCNO>
	<brief_summary>This study conduct identify pediatric patient Hunter syndrome neurodevelopmental disease characteristic , currently receive treatment Elaprase , may suitable participate clinical study investigational agent .</brief_summary>
	<brief_title>Screening Study Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence Central Nervous System ( CNS ) Involvement Who Are Currently Receiving Treatment With Elaprase®</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>1 . The patient male ≥3 &lt; 18 year age 2 . The patient currently receive weekly IV infusion Elaprase . 3 . The patient , patient 's parent ( ) , legally authorize guardian ( ) voluntarily sign Institutional Review Board / Independent Ethics Committeeapproved inform consent form relevant aspect study explain discussed patient . The guardian ' consent subject 's assent , relevant , must obtain . 1 . The patient CNS shunt . 2 . The patient receive hematopoietic stem cell transplant . 3 . The patient currently enrol clinical trial . 4 . The patient significant medical psychiatric comorbidity ( y ) might affect study data confound integrity study result .</criteria>
	<gender>Male</gender>
	<minimum_age>32 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>